Fascin, cortactin and survivin expression of melanocytic neoplasms and association with clinicopathological parameters and anatomic locations in Chinese people

European Journal of Dermatology

Volumn 20, Issue 3, 2010, Pages 293-301

  Gao, Hong Wei ^a   Yu, Cheng Ping ^a   Lee, Herng Sheng ^a   Nieh, Shin ^a   Chiang, Chien Ping ^a   Wang, Wei Ming ^a   Jin, Jong Shiaw ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cortactin; Fascin; Immunostaining scores; Melanocytic nevus; Melanoma; Survivin

Indexed keywords

CORTACTIN; FASCIN; SURVIVIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DYSPLASTIC NEVUS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MELANOMA; PROTEIN EXPRESSION; RISK FACTOR; SKIN METASTASIS; SURVIVAL RATE; SURVIVAL TIME;

ACTINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CHILD; CORTACTIN; CYTOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MICROFILAMENT PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEVUS, PIGMENTED; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN; SKIN NEOPLASMS; SURVIVAL RATE; TAIWAN; YOUNG ADULT;

EID: 77952815978     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0927     Document Type: Article

References (48)

1. Stevens NG, Liff JM, Weiss NS. Plantar melanoma: is the incidence of melanoma of the sole of the foot really higher in blacks than whites? Int J Cancer 1990; 45: 691-693.
2. Chen YJ, Wu CY, Chen JT, Shen JL, Chen CC, Wang HC. Clinicopathologic analysis of malignant melanoma in Taiwan. J Am Acad Dermatol 1999; 41: 945-949.
3. Coleman 3rd WP, Loria PR, Reed RJ, Krementz ET. Acral lentiginous melanoma. Arch Dermatol 1980; 116: 773-776.
4. Kukita A, Ishihara K. Clinical features and distribution of malignant melanoma and pigmented nevi on the soles of the feet in Japan. J Invest Dermatol 1989; 92: S210-3. (Pubitemid 19138772)
5. Ishihara K, Saida T, Yamamoto A. Updated statistical data for malignant melanoma in Japan. Int J Clin Oncol 2001; 6: 109-116. (Pubitemid 32634488)
6. Elwood JM. Melanoma and sun exposure. Semin Oncol 1996; 23: 650-666.
7. Murphy GM. Skin diseases with high public health impact. Melanoma. Eur J Dermatol 2007; 17: 559-562.
8. Clark Jr WH, Elder DE, Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986; 17: 443-450.
9. Clark Jr WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 9: 705-727.
10. Flotte TJ, Mihm Jr MC. Melanoma: the art versus the science of dermatopathology. Hum Pathol 1986; 17: 441-442.
11. Ackerman AB, David KM. A unifying concept of malignant melanoma: biologic aspects. Hum Pathol 1986; 17: 438-440. (Pubitemid 16061447)
12. Breuninger H, Kohler C, Drepper H, Bastian B, Brocker EB, Gohl J, et al. Is acrolentiginous melanoma (ALM) more malignant than superficially spreading melanoma (SSM) at a high-risk site? A matched-pair comparison between 113 ALM and SSM within the scope of a multicenter study. Hautarzt 1994; 45: 529-531.
13. Janet L. Maldonado JF, Hetal Patel, Ajay N. Jain, Klaus Busam, Toshiro Kageshita, Tomomichi Ono et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95: 1878-1880.
14. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346.
15. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
16. Glatz-Krieger K, Pache M, Tapia C, et al. Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization. Virchows Arch 2006; 449: 328-333.
17. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95: 1878-1890.
18. Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T, Borisy GG. Role of fascin in filopodial protrusion. J Cell Biol 2006; 174: 863-875.
19. Adams JC. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 2004; 16: 590-596.
20. Wu H, Parsons JT. Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol 1993; 120: 1417-1426.
21. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005; 96: 379-386. (Pubitemid 41179738)
22. van Rossum AG, Gibcus J, van der Wal J, Schuuring E. Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells. Breast Cancer Res 2006; 7: 235-237. (Pubitemid 41830158)
23. Williams ME, Gaffey MJ, Weiss LM, Wilczynski SP, Schuuring E, Levine PA. Chromosome 11Q13 amplification in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1993; 119: 1238-1243. (Pubitemid 23339141)
24. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584. (Pubitemid 28563719)
25. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921. (Pubitemid 27353455)
26. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999; 341: 452-453. (Pubitemid 29362524)
27. Piras F, Murtas D, Minerba L, Ugalde J, Floris C, Maxia C, et al. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology 2007; 50: 835-842. (Pubitemid 46850069)
28. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 2001; 20: 6418-6434.
29. Daly RJ. Cortactin signalling and dynamic actin networks. Biochem J 2004; 382: 13-25. (Pubitemid 39141561)
30. Xie JJ, Xu LY, Zhang HH, Cai WJ, Mai RQ, Xie YM, et al. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun 2005; 337: 355-362.
31. Luo ML, Shen XM, Zhang Y, Wei F, Xu X, Cai Y, et al. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 2006; 66: 11690-11699. (Pubitemid 46094181)
32. Hofman P, Butori C, Havet K, Hofman V, Selva E, Guevara N, et al. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. Br J Cancer 2008; 98: 956-964. (Pubitemid 351341605)
33. Tsai WC, Jin JS, Chang WK, Chan DC, Yeh MK, Cherng SC, et al. Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters. J Histochem Cytochem 2007; 55: 955-962. (Pubitemid 47293841)
34. Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, Tsunoda S, et al. Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11: 2597-2605. (Pubitemid 40569459)
35. Helige C, Zellnig G, Hofmann-Wellenhof R, Fink-Puches R, Smolle J, Tritthart HA. Interrelation of motility, cytoskeletal organization and gap junctional communication with invasiveness of melanocytic cells in vitro. Invasion Metastasis 1997; 17: 26-41. (Pubitemid 27525065)
36. Yildiz L, Kefeli M, Aydin O, Kandemir B. Fascin expression in melanocytic lesions of the skin. Eur J Dermatol 2009; 19: 445-450.
37. Ponnelle T, Chapusot C, Martin L, Bouvier AM, Plenchette S, Faivre J, et al. Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol 2005; 131: 504-510. (Pubitemid 41215305)
38. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005; 4: 11. (Pubitemid 41460847)
39. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, et al. Identification of a novel splice variant of the human antiapoptopsis gene survivin. Biochem Biophys Res Commun 2004; 314: 902-907. (Pubitemid 38112885)
40. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002; 9: 1334-1342. (Pubitemid 36097703)
41. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-6102.
42. Li F, Ling X. Survivin study: an update of "what is the next wave"? J Cell Physiol 2006; 208: 476-486.
43. Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, et al. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 2005; 49: 353-361.
44. Caldas H, Fangusaro JR, Boue DR, Holloway MP, Altura RA. Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis. Blood 2007; 109: 1479-1489.
45. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2008; 30: 117-122.
46. Florell SR, Bowen AR, Hanks AN, Murphy KJ, Grossman D. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol 2005; 32: 45-49.
47. Vetter CS, Muller-Blech K, Schrama D, Brocker EB, Becker JC. Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch Dermatol Res 2005; 297: 26-30.
48. Ding Y, Prieto VG, Zhang PS, Rosenthal S, Smith KJ, Skelton HG, et al. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer 2006; 106: 1123-1129.